Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Douglas Figg

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
Pharmacologic biomarkers in the development of stratified cancer medicineWilliam Douglas Figg, David R Newell
Clinical Genitourinary Cancer|October 10, 2006
Assessing progress against prostate cancerOliver Sartor, Tania Alchalabi, William Douglas Figg
Cancer Biology & Therapy|March 10, 2009
NCI designated cancer center funding not influenced by organizational structureMargaret E Wolfe, Daniel Yagoda, Paul W Thurman, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 17, 2013
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitroChris Mahony, Lynda Erskine, Jennifer Niven, et al.
Vox Sanguinis|September 30, 2020
Pharmacogenomics with red cells: a model to study protein variants of drug transporter genesWilly Albert Flegel, Kshitij Srivastava, Tristan Michael Sissung, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2014
Reply to D’Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryosNeil Vargesson, Chris Mahony, Lynda Erskine, et al.
Chemotherapy Research and Practice|February 8, 2012
The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 InhibitorXiaobing Liang, Yi Guo, William Douglas Figg, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2013
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinomaMingqian Feng, Wei Gao, Ruoqi Wang, et al.
Journal of Clinical Pharmacology|April 9, 2014
Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizersRichard B Horenstein, Rajnikanth Madabushi, Issam Zineh, et al.
Journal of the American Pharmacists Association : Japha|May 16, 2009
U.S. Public Health Service Commissioned Corps pharmacists: making a difference in advancing the nation's healthLouis Flowers, Jeannette Wick, William Douglas Figg, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
Pharmacologic biomarkers in the development of stratified cancer medicineWilliam Douglas Figg, David R Newell
Clinical Genitourinary Cancer|October 10, 2006
Assessing progress against prostate cancerOliver Sartor, Tania Alchalabi, William Douglas Figg
Cancer Biology & Therapy|March 10, 2009
NCI designated cancer center funding not influenced by organizational structureMargaret E Wolfe, Daniel Yagoda, Paul W Thurman, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 17, 2013
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitroChris Mahony, Lynda Erskine, Jennifer Niven, et al.
Vox Sanguinis|September 30, 2020
Pharmacogenomics with red cells: a model to study protein variants of drug transporter genesWilly Albert Flegel, Kshitij Srivastava, Tristan Michael Sissung, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2014
Reply to D’Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryosNeil Vargesson, Chris Mahony, Lynda Erskine, et al.
Chemotherapy Research and Practice|February 8, 2012
The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 InhibitorXiaobing Liang, Yi Guo, William Douglas Figg, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2013
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinomaMingqian Feng, Wei Gao, Ruoqi Wang, et al.
Journal of Clinical Pharmacology|April 9, 2014
Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizersRichard B Horenstein, Rajnikanth Madabushi, Issam Zineh, et al.
Journal of the American Pharmacists Association : Japha|May 16, 2009
U.S. Public Health Service Commissioned Corps pharmacists: making a difference in advancing the nation's healthLouis Flowers, Jeannette Wick, William Douglas Figg, et al.
Pageof 3